Vancomycin-resistant Enterococcus

Study Published in Science Translational Medicine Shows Exbaq’s Experimental Vaccine Protects Against Many of the Most Dangerous Antibiotic Resistant Superbugs Causing Hospital Acquired Infections

Retrieved on: 
Thursday, October 5, 2023
Patent, Partnership, Klebsiella pneumoniae, Infection, Methicillin-resistant Staphylococcus aureus, Homeland, Homeland security, Innovation, Acinetobacter baumannii, IND, Fungus, National Institute of Allergy and Infectious Diseases, Fungal infection, Hulk, Laboratory, Pseudomonas aeruginosa, Patient, FDA, Mucormycosis, R01, Macrophage, Escherichia coli, Immune system, USC, Bangladesh Technical Education Board, Vancomycin-resistant Enterococcus, ESBL, Korea Disease Control and Prevention Agency, Blood, Enterococcus, Translational medicine, Denise Spellberg, NIH, Vaccine, Pharmaceutical industry, Klebsiella, Science

Multiple studies in different laboratories have confirmed the vaccine protected against serious infections within 24 hours and lasts for up to 28 days.

Key Points: 
  • Multiple studies in different laboratories have confirmed the vaccine protected against serious infections within 24 hours and lasts for up to 28 days.
  • Early data suggest that a second dose may extend the window to prevent infection.
  • The study was published in Science and Translational Medicine.
  • These infections are often caused by highly antibiotic-resistant superbugs, many of which are targeted by this new ExBaq vaccine.

CHOP-led Study Shows that Antibiotic-Resistant Microbes in the Gut Make C. difficile More Infectious

Retrieved on: 
Wednesday, November 16, 2022
Health, Doctor of Philosophy, University of Minnesota Medical School, Philadelphia, Hospital, Clostridioides difficile infection, RNA, IBD, Infection, VRE, Prussia, University of Virginia, Environment, Collection, Metabolomics, Clostridioides difficile (bacteria), University, Vancomycin-resistant Enterococcus, Vanderbilt University School of Medicine, Assistant, Ornithine, Pathology, Research, Association, Organic acid, Patient, Nutrient, Inflammatory bowel disease, University of Florida, University of Pittsburgh, Children's Hospital of Philadelphia, DOI, Medical laboratory, Virulence, Arginine, Gastrointestinal tract, CHOP, Public health, Dietary supplement, Pharmaceutical industry, Nature, Child, Enterococcus

PHILADELPHIA, Nov. 16, 2022 /PRNewswire/ -- Clostridioides difficile, often referred to as C. difficile or C. diff, is a bacterium that causes severe intestinal illness and, as its name suggests, can be difficult to study and treat. Approximately 1 in 6 patients infected with C. difficile will be reinfected within two months. Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others. The human gut is filled with trillions of microbes, and these microbes influence the virulence of various pathogens, but until now, scientists had little understanding of how C. difficile cooperates with the rich collection of microorganisms in the gastrointestinal tract.

Key Points: 
  • Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others.
  • Prior studies have shown that adults infected with C. difficile also have high levels of Enterococcus in their gut and that vancomycin-resistant Enterococcus (VRE) frequently co-infects patients with C. difficile.
  • They also observed a positive correlation between C. difficile burdens and ornithine, supporting a key role for this amino acid in C. difficile infection.
  • difficile."

UMF Corporation Calls for Nominations for 14th Annual National Hygiene Specialist® Excellence Award

Retrieved on: 
Thursday, November 10, 2022
Hospital, Methicillin-resistant Staphylococcus aureus, EVS, Research, Disinfectant, Risk, Health, Education, VRE, Death, Multimedia, CDC, Staphylococcus, View, Virus, Paola Lattus, Science, Patient, Bacteria, UMF, Vancomycin-resistant Enterococcus, Infection, Enterococcus, Clostridioides difficile (bacteria), MRSA, COVID-19, Pharmaceutical industry, Medicine

NORTHBROOK, Ill., Nov. 10, 2022 /PRNewswire/ -- UMF Corporation is pleased to announce that nominations are open for the 14th annual National Hygiene Specialist® Excellence Award, which acknowledges the environmental services (EVS) workers who play essential roles in reducing preventable healthcare associated infections (pHAIs). pHAIs are among the leading causes of death in the United States. Infecting 1 in 25 hospitalized patients annually, pHAIs put patients at risk, significantly increase the number of hospital days required, and add to healthcare costs. EVS staff are crucial when it comes to controlling pHAIs, which include superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA), Clostridioides difficile (C. diff), Vancomycin-resistant Enterococcus (VRE), and COVID-19. Nominations are open through Dec. 31, 2022.

Key Points: 
  • NORTHBROOK, Ill., Nov. 10, 2022 /PRNewswire/ -- UMF Corporation is pleased to announce that nominationsare open for the 14th annual National Hygiene Specialist Excellence Award , which acknowledges the environmental services (EVS) workers who play essential roles in reducing preventable healthcare associated infections (pHAIs).
  • "In the United States, infections acquired in healthcare facilities kill more than 75,000 people every year," said UMF CEO George Clarke.
  • While we established our National Hygiene Specialist Excellence Award more than a decade ago, it has never been more important to acknowledge and celebrate these workers who serve as a first line of defense in preventing the spread of pHAIs."
  • The National Hygiene Specialist Excellence Award is an opportunity to recognize their critical contributions.

PPG earns prestigious R&D 100 Awards for antimicrobial, antiviral paints

Retrieved on: 
Tuesday, August 30, 2022
General Health, Architecture, Other Construction & Property, Residential Building & Real Estate, Infectious Diseases, Commercial Building & Real Estate, Other Manufacturing, Construction & Property, Chemicals, Plastics, COVID-19, Health, Interior Design, Manufacturing, Escherichia coli, COVID-19, Klebsiella pneumoniae, Technology, Research, Staphylococcus aureus, Awareness, Virus, Feline calicivirus, Method, S.A, Coronavirus, Advantage Business Media, Klebsiella aerogenes, Paint, VRE, ISO, Creativity, Severe acute respiratory syndrome coronavirus 2, Opacity, Industry, Pseudomonas aeruginosa, Partnership, Escherichia, Industrial Research Limited, R, Laboratory, Hospital, R&D, Science and technology, School, JIS, Health, ATCC, NYSE, Comex, Vancomycin-resistant Enterococcus, Disinfectant, Enterococcus faecium, Evaluation, MRSA, Nursing, Enterobacter, Corning Inc., Knowledge, Bacteria, Copper, Float glass, Fine chemical, Chemical, Science, Salmonella, PPG, H1N1, Corning

PPG (NYSE:PPG) today announced that two of its industry-leading antimicrobial and antiviral products have been recognized with 2022 R&D 100 Awards in the Mechanical/Materials category COPPER ARMORTM antimicrobial paint by PPG with Corning Guardiant technology and COMEX VINIMEX TOTAL antiviral and antibacterial paint.

Key Points: 
  • PPG (NYSE:PPG) today announced that two of its industry-leading antimicrobial and antiviral products have been recognized with 2022 R&D 100 Awards in the Mechanical/Materials category COPPER ARMORTM antimicrobial paint by PPG with Corning Guardiant technology and COMEX VINIMEX TOTAL antiviral and antibacterial paint.
  • The R&D 100 Awards Committee and R&D World magazine honor the 100 most innovative technologies and services of the past year with the R&D 100 Awards.
  • PPG has earned 34 R&D 100 Awards through the years.
  • Since 1963, the R&D 100 Awards program has identified revolutionary technologies newly introduced to the market and celebrated the top technology products of the year.

PPG Receives EPA Registration for COPPER ARMOR Paint Powered by Corning® Guardiant® Technology, Proven to Kill Bacteria and Viruses, Including SARS CoV-2, The Virus That Causes COVID-19

Retrieved on: 
Tuesday, October 5, 2021
Residential Building & Real Estate, Other Retail, Commercial Building & Real Estate, Manufacturing, Construction & Property, Health, Interior Design, Other Manufacturing, Infectious Diseases, Retail, Home Goods, Escherichia coli, Invention, VOC, Partnership, Evaluation, RD&E, Methicillin-resistant Staphylococcus aureus, Engineering, Corning Inc., VRE, Vancomycin-resistant Enterococcus, EPA, Bacteria, Virus, Enterococcus faecium, MRSA, Pseudomonas aeruginosa, United States Environmental Protection Agency, Staphylococcus aureus, Enterobacter, Science, Creativity, Severe acute respiratory syndrome coronavirus 2, Klebsiella pneumoniae, SARS, Klebsiella aerogenes, Work, Copper, NYSE, Staphylococcus, Feline calicivirus, Paint

PPG Copper Armor with Corning Guardiant technology is the first virus killing paint in the U.S., and will provide an extra layer of protection on the walls that surround us where we live, work and learn.

Key Points: 
  • PPG Copper Armor with Corning Guardiant technology is the first virus killing paint in the U.S., and will provide an extra layer of protection on the walls that surround us where we live, work and learn.
  • PPG Copper Armor also provides a mold- and mildew-resistant coating on the dry paint film.
  • Available in eggshell, satin and semi-gloss, PPG Copper Armor can be tinted to more than 600 colors from the PPG paint palette.
  • To learn more about PPG Copper Armor paint and to find a store near you, visit www.ppgpaints.com/copper-armor .

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021

Retrieved on: 
Thursday, August 12, 2021
Methicillin-resistant Staphylococcus aureus, Gram, DNA, IIIC, Company, Gram-positive bacteria, Infection, Investor, MRSA, Vancomycin-resistant Enterococcus, VRE, PRSP, Antibiotics

This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci.

Key Points: 
  • This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci.
  • As time permits, Mr. Luci may be able to respond to questions from participants.
  • Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com .

‍Pharmacy and Healthcare Professionals Nationwide Recognize Patient Safety Benefits of New Consensus Vancomycin Dosing Guidelines, But Fewer than One in Three Plan to Adopt Them

Retrieved on: 
Wednesday, July 8, 2020
Infectious diseases, Chemistry, Healthcare quality, Glycopeptide antibiotics, Physical sciences, RTT, Eli Lilly and Company, Total synthesis, Vancomycin, Patient safety, Antibiotic, Vancomycin-resistant Enterococcus

According to the findings of a survey released today by InsightRX , 98% of pharmacy and healthcare professionals nationwide said they personally believe that the new vancomycin guidelines are important for patient safety.

Key Points: 
  • According to the findings of a survey released today by InsightRX , 98% of pharmacy and healthcare professionals nationwide said they personally believe that the new vancomycin guidelines are important for patient safety.
  • "Vancomycin, like many other medications, requires tailored dosing regimens to maximize patient efficacy and safety," said InsightRX CEO Sirj Goswami, PhD.
  • "The antibiotic is highly effective in combating infections caused by staph bacteria, but its effects vary significantly from person to person."
  • "Respondents are nearly unanimous in their personal belief that the new consensus guidelines are important for patient safety," said Goswami.

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 9, 2020
Infectious diseases, Pharmaceutical, Health, Bacteria, Lactobacillales, Infectious diseases, RTT, Chemistry, Glycopeptide antibiotics, Antibiotic-resistant bacteria, Vancomycin-resistant Enterococcus, Enterococcus faecium, Vancomycin, Enterococcus, Enterococcus gallinarum

The "Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

With Superbugs and Antibiotic Resistance on the Rise, VA Facilities Make Infection Prevention a Priority

Retrieved on: 
Tuesday, September 10, 2019
Biotechnology, Technology, Health, Defense, Other Technology, Other Defense, Infectious diseases, General Health, Hospitals, Hardware, Medical specialties, Infectious diseases, Medicine, Healthcare-associated infections, Antibiotic-resistant bacteria, Bacterial diseases, Epidemiology, Vancomycin-resistant Enterococcus, Vancomycin, Infection control, Infection rate, Staphylococcus aureus

Xenex is a world leader in infection prevention programs and room disinfection technology.

Key Points: 
  • Xenex is a world leader in infection prevention programs and room disinfection technology.
  • To help government healthcare facilities improve their infection prevention programs, Xenex partnered with Geo-Med, LLC , which provides a broad range of medical and surgical products to Veterans Health Administration medical centers and DOD military treatment facilities.
  • HAIs are caused by microorganisms such as Clostridium difficile (C.diff), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE), which are rampant in healthcare facilities.
  • To combat these dangerous microorganisms and help facilities achieve infection rate reductions, Xenex bundles LightStrike robots with its infection prevention (IP) expertise, customized disinfection protocols, and consulting and account management services into a hospitals comprehensive infection prevention program.

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 22, 2019
Health, Infectious diseases, Pharmaceutical, Bacteria, Lactobacillales, Chemistry, Infectious diseases, RTT, Glycopeptide antibiotics, Antibiotic-resistant bacteria, Vancomycin-resistant Enterococcus, Vancomycin, Enterococcus faecium, Enterococcus, Enterococcus gallinarum

The "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Vancomycin-Resistant Enterococcus Faecium Infections development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active Vancomycin-Resistant Enterococcus Faecium Infections pipeline products by developmental stage, product type, molecule type, and administration route.